Welcome to our dedicated page for C4 Therapeutics SEC filings (Ticker: CCCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The C4 Therapeutics, Inc. (CCCC) SEC filings page on Stock Titan provides structured access to the companys regulatory disclosures as filed with the U.S. Securities and Exchange Commission. C4 Therapeutics is a clinical-stage biopharmaceutical company listed on The Nasdaq Global Select Market, and its filings offer detail on clinical progress, collaborations, financings and corporate governance related to its targeted protein degradation programs.
Investors can use this page to review Form 8-K current reports in which C4 Therapeutics furnishes quarterly financial results, business highlights and updates on key clinical programs such as cemsidomide, an investigational IKZF1/3 degrader in development for relapsed/refractory multiple myeloma and non-Hodgkins lymphoma. 8-K filings also document material events including the clinical trial collaboration and supply agreement with Pfizer for elranatamab, underwritten equity offerings involving common stock and warrants, and stockholder approvals to increase authorized shares.
In addition to event-driven 8-Ks, the companys shelf registration statements, prospectus supplements and related exhibits describe the terms of securities offerings used to fund its pipeline, including cemsidomide, CFT8919 and other degrader programs. Governance-related filings, such as amendments to the certificate of incorporation and annual meeting voting results, provide insight into C4 Therapeutics capital structure and board-level decisions.
On Stock Titan, these SEC documents are complemented by AI-powered summaries that highlight the most important points in each filing, helping readers quickly understand topics like new clinical data disclosures, changes in collaboration arrangements, or the impact of financings on cash runway. Users interested in CCCC can consult this page to follow how C4 Therapeutics reports its clinical, financial and corporate developments through official SEC channels over time.
C4 Therapeutics form 4 disclosure: A company director, Kenneth Carl Anderson, acquired 5,349 shares of C4 Therapeutics common stock as compensation in lieu of cash, at a price equal to the stock's closing market price of $2.15 on the transaction date. After the issuance, the reporting person directly beneficially owns 140,574 shares and reports additional indirect holdings through trusts and a spouse totaling multiple separate share blocks: 47,316 (spouse), 61,265 (2016 GRAT), 61,265 (spouse's 2016 GRAT), 16,939 (2015 irrevocable trust), and 16,939 (spouse's 2015 irrevocable trust). The filing states these trust-held shares are disclaimed except to the extent of pecuniary interest. The acquisition was made under the issuer's Non-Employee Director Compensation Policy, reflecting an election to take equity instead of cash for board service.
Donna Grogan, a non-employee director of C4 Therapeutics, Inc. (CCCC), received 6,740 shares of common stock on 10/01/2025 by electing to take equity in lieu of cash under the company’s Non-Employee Director Compensation Policy. The shares were recorded at a per-share price of $2.15, equal to the closing market price on the transaction date. After the grant, the reporting person beneficially owned 58,629 shares, held directly. The Form 4 discloses the transaction code and confirms the shares were issued as director compensation.
C4 Therapeutics, Inc. announced on
C4 Therapeutics, Inc. (CCCC) reported that it issued a press release and presented clinical data from its Phase 1 trial of cemsidomide plus dexamethasone for relapsed/refractory multiple myeloma at the International Myeloma Society (IMS) Meeting in an oral presentation on September 20, 2025. The company furnished the press release as Exhibit 99.1 and posted the presentation slides on its investor relations site, filing those slides as Exhibit 99.2 to this Current Report on Form 8-K. The filing states these materials are "furnished" (not "filed") and does not include financial results or detailed trial outcomes within the Form text. The company also notes the furnishing does not constitute an admission as to materiality.
C4 Therapeutics insider filing: The reporting person, Kendra Adams (CFO), acquired 6,250 shares of common stock on 09/18/2025 upon vesting of previously granted restricted stock units (RSUs). The shares were issued at no cash price upon vesting and increased her beneficial holdings to 165,117 shares. In connection with the vesting, the issuer withheld 2,775 shares to satisfy tax withholding obligations, which reduced the net shares delivered and left 162,342 shares listed after the withholding entry on the Form 4.
C4 Therapeutics (NASDAQ: CCCC) Q2 2025 10-Q highlights
- Revenue: $6.5 m from collaborations, down 46 % YoY (Q2 24: $12.0 m) as Biogen–related income rolled off.
- Expenses: R&D $26.2 m (+10 % YoY); G&A $8.8 m (-10 % YoY). Total op-ex $35.0 m (+4 %).
- Losses: Operating loss widened to $28.5 m; net loss $26.0 m (-$0.37 pps) versus $17.7 m (-$0.26 pps) a year ago. 1H 25 net loss $52.3 m.
- Cash runway: Cash, cash equivalents & marketable securities were $223 m at 6-30-25 (vs. $267 m at 12-31-24); management projects ≥12-month runway.
- Balance sheet: Deferred revenue $43.8 m, reflecting future work under Roche, MKDG, Merck and Betta deals; no debt.
- Collaboration momentum: Earned $1 m discovery milestone (MKDG) and two $2 m lead-series milestones (Roche). Q2 revenue mix: MKDG 53 %, Roche 30 %, Merck 16 %, Betta 1 %.
- Share count: 71.2 m outstanding (7-29-25) after equity comp and ESPP; authorized shares doubled to 300 m.
- Guidance & risk: Company remains clinical-stage with no product sales; relies on external funding and partner milestones; accumulated deficit $686 m.
The filing affirms strategic focus on protein-degrader oncology programs (e.g., CFT8919, DACs) while controlling G&A. Near-term catalysts hinge on progress within partnered pipelines and internal Phase 1 assets.
FAQ
What is the current stock price of C4 Therapeutics (CCCC)?
What is the market cap of C4 Therapeutics (CCCC)?
